ThromboGenics’ JETREA® Gains Approval in Taiwan
Leuven, September 2, 2014 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that JETREA® (ocriplasmin) has been approved in Taiwan. The approval has been granted following priority review by the Taiwan health authority.
Taiwan is the third country in Asia to grant JETREA® approval, following approvals in Singapore and Malaysia.
ThromboGenics’ partner Alcon, which is commercializing JETREA® outside the US, will be responsible for the launch of the drug in Taiwan.